Journal
SCIENCE SIGNALING
Volume 7, Issue 357, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aaa1877
Keywords
-
Categories
Funding
- Duke University School of Medicine start-up funds
- Duke Cancer Institute
- NIH Building Interdisciplinary Research Careers in Women's Health Program
- Harry J. Lloyd Trust Translational Research Award
- Golfers Against Cancer Research Award
- Stewart Trust Fellowship
- V Scholar Award from the V Foundation for Cancer Research
- NIH [CA103866, AI07389, R37DK048807]
Ask authors/readers for more resources
Cancer cells can activate diverse signaling pathways to evade the cytotoxic action of drugs. Wecreated and screened a library of barcoded pathway-activating mutant complementary DNAs to identify those that enhanced the survival of cancer cells in the presence of 13 clinically relevant, targeted therapies. We found that activation of the RAS-MAPK (mitogen-activated protein kinase), Notch1, PI3K (phosphoinositide 3-kinase)-mTOR (mechanistic target of rapamycin), and ER (estrogen receptor) signaling pathways often conferred resistance to this selection of drugs. Activation of the Notch1 pathway promoted acquired resistance to tamoxifen (an ER-targeted therapy) in serially passaged breast cancer xenografts in mice, and treating mice with a g-secretase inhibitor to inhibit Notch signaling restored tamoxifen sensitivity. Markers of Notch1 activity in tumor tissue correlated with resistance to tamoxifen in breast cancer patients. Similarly, activation of Notch1 signaling promoted acquired resistance toMAPKinhibitors inBRAFV600Emelanoma cells in culture, and the abundance of Notch1 pathway markers was increased in tumors from a subset ofmelanoma patients. Thus, Notch1 signalingmay be a therapeutic target in some drug-resistant breast cancers and melanomas. Additionally, multiple resistance pathways were activated in melanoma cell lines with intrinsic resistance to MAPK inhibitors, and simultaneous inhibition of these pathways synergistically induced drug sensitivity. These data illustrate the potential for systematic identification of the signaling pathways controlling drug resistance that could inform clinical strategies and drug development for multiple types of cancer. This approach may also be used to advance clinical options in other disease contexts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available